Endothelial FunctionPhase 4NCT02500329
Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients
A Phase 4 study testing Gemigliptin and Acarbose in people with Endothelial Function and Type 2 Diabetes, run by Seoul National University Hospital at 1 site in South Korea.
Trial summary
This is a phase 4, single center, randomized, open-labeled study. The primary objective of the study is to compare effect of gemigliptin and acarbose on endothelial function. Subjects are randomized to gemigliptin or acarbose group and maintained intial treatment for 4 weeks. Read more about this study
- Who is it for?
- Ages 20 to 80 years
- Conditions the study is for
- Endothelial Function, Type 2 Diabetes, Gemigliptin
- What is being tested?
- Gemigliptin and Acarbose
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 54 participants
- Where
- 1 siteSouth Korea
- Study dates
- Sep 2014to Dec 2015
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- age: 20-80yrs
- patients with type 2 diabetes (duration of diabetes >=3 months)
- HbA1c :>7.0 and <=9.0% on metformin monotherapy
- no changes on medications during recent 3 months.
Who cannot join
- patients with type 1 diabetes
- history of medications including α-glucosidase inhibitor, glinide, GLP-1 analogue, other DPP-4 Inhibitors, or insulin during recent 3 months.
- history of acute diabetic complication, acute coronary events, or coronary bypass surgery/interventions during recent 6 months.
- patients with congestive heart failure (NYHA II~IV) or clinically significant ventricular arrhythmia
- serum ALT or AST> 2.5 x upper normal range
- serum direct bilirubin > 1.3 x upper normal range
Show all 10Show fewer
- serum creatinine > (men) 1.5 mg/dL, (women)>1.4 mg/dL
- smoker
- pregnant women, or breast-feeding women
- medication with acetylsalicylic acid or vitamin K antagonist
Trial locations and contacts
1 site in 1 country.
South Korea1 site, 1 recruiting
- Recruiting
Boramae medical center
Seoul, 156-707
Bokyung Koo, bokyungkoomd@gmail.com
Min Kyong Moon
About this study
Official title: Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients (GetUp Trial)
This is a phase 4, single center, randomized, open-labeled study. The primary objective of the study is to compare effect of gemigliptin and acarbose on endothelial function.
Subjects are randomized to gemigliptin or acarbose group and maintained intial treatment for 4 weeks.
- Conditions
- Endothelial Function, Type 2 Diabetes, Gemigliptin, Acarbose
- Being tested
- Gemigliptin, Acarbose
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GemigliptinDrug
Gemigliptin for 4 weeks
AcarboseDrug
Acarbose for 4 weeks
| Study group | Role | What they receive |
|---|---|---|
| gemigliptin | Experimental | gemigliptin for 4 weeks Receives: Drug: Gemigliptin |
| acarbose | Active comparator | acarbose for 4 weeks Receives: Drug: Acarbose |
What is being measured
The primary outcome is the main question the study is designed to answer.
endothelial function (reactive hyperemic index)
Measured: 4 weeks
Secondary outcomes (3)
Fasting plasma glucose
Measured: 4 weeks
Postprandial 2hour glucose
Measured: 4 weeks
Glycated albumin
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2015 (estimated)
- Study startSep 2014
- Primary completionDec 2015 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Endothelial FunctionStudies of the same condition, open and under way.
- More trials run by Seoul National University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 54 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Seoul National University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Min Kyong Moon, Seoul National University Hospital
- Investigators
- Min Kyong Moon, Principal investigator, Boramae medical center, 20 Boramae-ro 5-gil,Dongjak-Gu,Seoul 156-707, Korea
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02500329
- Sponsor's protocol ID
- BRMH 26-2014-124
- Status last verified
- Jul 2015
- First submitted
- 12 Jul 2015
- Last updated
- 16 Jul 2015
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients (GetUp Trial)
- ClinicalTrials.gov ID
- NCT02500329
- Acronym / sponsor ID
- BRMH 26-2014-124
- Conditions
- Endothelial Function, Type 2 Diabetes, Gemigliptin, Acarbose
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 54 participants (estimated)
- Lead sponsor
- Seoul National University HospitalUniversity, hospital or other
- Study start
- Sep 2014
- Primary completion
- Dec 2015 (estimated)
- First posted
- 16 Jul 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a phase 4, single center, randomized, open-labeled study. The primary objective of the study is to compare effect of gemigliptin and acarbose on endothelial function.
Subjects are randomized to gemigliptin or acarbose group and maintained intial treatment for 4 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| gemigliptin | Experimental | Drug: Gemigliptingemigliptin for 4 weeks |
| acarbose | Active comparator | Drug: Acarboseacarbose for 4 weeks |
Who may qualify
- Ages
- 20 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- age: 20-80yrs
- patients with type 2 diabetes (duration of diabetes >=3 months)
- HbA1c :>7.0 and <=9.0% on metformin monotherapy
- no changes on medications during recent 3 months.
Key exclusion criteria (10 listed)
- patients with type 1 diabetes
- history of medications including α-glucosidase inhibitor, glinide, GLP-1 analogue, other DPP-4 Inhibitors, or insulin during recent 3 months.
- history of acute diabetic complication, acute coronary events, or coronary bypass surgery/interventions during recent 6 months.
- patients with congestive heart failure (NYHA II~IV) or clinically significant ventricular arrhythmia
- serum ALT or AST> 2.5 x upper normal range
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GemigliptinGemigliptin for 4 weeks | Drug | gemigliptin |
| AcarboseAcarbose for 4 weeks | Drug | acarbose |
Primary outcome
endothelial function (reactive hyperemic index)
Time frame: 4 weeks
3 secondary outcomes
Fasting plasma glucose
Time frame: 4 weeks
Postprandial 2hour glucose
Time frame: 4 weeks
Glycated albumin
Time frame: 4 weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2015.
Related trials for Endothelial Function
Not yet recruiting
Effect of Propionic Acid Supplementation on Endothelial Function
Cardiovascular Diseases, Endothelial Dysfunction
Active, not recruiting
Vascular Aging and Lp299v Study in Healthy Adults
Vascular Aging
Active, not recruiting
Impact of Lp299v on Vascular Function in Patients With PASC
COVID-19
Not yet recruitingObservational study
Vascular Health and Function in Cystic Fibrosis
Cystic Fibrosis, Endothelial Dysfunction
Recruiting
Hemodynamics After Resistance Training
Perimenopause
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Min Kyong Moon principal investigator
Boramae medical center, 20 Boramae-ro 5-gil,Dongjak-Gu,Seoul 156-707, Korea
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Gemigliptin and Acarbose in people with Endothelial Function and Type 2 Diabetes, run by Seoul National University Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 16 Jul 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Min Kyong Moon (+82-2-870-2226, mkmoon@snu.ac.kr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
endothelial function (reactive hyperemic index) (time frame: 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2015.